Key points are not available for this paper at this time.
Abstract Data obtained retrospectively from a group of patients with chronic granulocytic leukemia provided the basis for characterizing the onset of the terminal phase of chronic granulocytic leukemia. Such characterization permits an opportunity to introduce in sufficient time new therapeutic agents for the treatment of a phase of a disease which heretofore has been refractory to conventional therapy. The suggested criteria marking the onset of the terminal phase may require revision as more information is systematically collected in the future.
Karanas et al. (Sun,) studied this question.